Warren Cresswell has previously worked in senior management roles for 17 years at the Danish diagnostics company Dako and after that he spent five years, three of which as CEO, at Prometheus Laboratories, a diagnostics start-up that was acquired by Nestlé Health Science.
“Warren contributes with experience of developing and lead commercially successful organizations. With 25 years of experience from the diagnostics industry, he brings with him an extensive network and valuable knowledge about the American market within the field of oncology. Warren is an important piece of the puzzle in Biovica's market introduction of DiviTum®TKa,” said Anders Rylander, CEO of Biovica.
“I am thrilled to join the team at Biovica. DiviTum®TKa promises great value for patients and payers, and a fantastic commercial potential. I look forward to contributing to this exciting journey,” said Warren Cresswell, President Americas of Biovica.
Warren Cresswell holds a Bachelor´s Degree in Chemistry from California State University Northridge and an MBA from the University of Pittsburgh. He started at Biovica on August 1.